OncRef

Clinical Trial: NCT00066573

Exemestane or Anastrozole in Treating Postmenopausal Women Who Have Undergone Surgery for Primary Breast Cancer

Status:

COMPLETED

Phase:

Phase 3

Lead Sponsor:NCIC Clinical Trials Group
Information Provided By:Canadian Cancer Trials Group
Last Update Posted:2023-08-25

Study Overview

Brief Summary

RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy, using exemestane or anastrozole, may fight breast cancer by reducing the production of estrogen. It is not yet known whether exemestane is more effective than anastrozole in preventing the recurrence of breast cancer.

PURPOSE: This randomized phase III trial is studying exemestane to see how well it works compared to anastrozole in preventing cancer recurrence in postmenopausal women who have undergone surgery for primary breast cancer.

Official Title

A Randomized Phase III Trial Of Exemestane Versus Anastrozole In Postmenopausal Women With Receptor Positive Primary Breast Cancer

Conditions

Breast Cancer

Intervention / Treatment

  • Drug: anastrozole
  • Drug: exemestane

Other Study ID Numbers

  • MA27
  • CAN-NCIC-MA27
  • NCCTG-MA27
  • CALGB-CAN-NCIC-MA27
  • ECOG-CAN-NCIC-MA27
  • SWOG-CAN-NCIC-MA27
  • IBCSG-30-04
  • 2005-001893-28
  • CDR0000316325
  • 2005

Start Date (Actual)

2003-06-06

Primary Completion Date (Actual)

2010-11-07

Study Completion Date (Actual)

2012-01-06

Enrollment (Actual)

7576

Study Type

Interventional

Phase

Phase 3